Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $20.51, but opened at $19.32. Capricor Therapeutics shares last traded at $19.41, with a volume of 509,478 shares trading hands.
Analyst Ratings Changes
A number of equities analysts recently commented on CAPR shares. Maxim Group upped their target price on Capricor Therapeutics from $12.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, September 25th. Oppenheimer reaffirmed an "outperform" rating and issued a $15.00 target price on shares of Capricor Therapeutics in a research report on Monday, September 23rd. Cantor Fitzgerald reiterated an "overweight" rating and set a $8.00 price target on shares of Capricor Therapeutics in a research report on Friday, September 20th. Finally, HC Wainwright restated a "buy" rating and issued a $40.00 price objective on shares of Capricor Therapeutics in a report on Wednesday, October 9th. One analyst has rated the stock with a sell rating and five have given a buy rating to the stock. According to data from MarketBeat, Capricor Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $22.60.
View Our Latest Stock Analysis on Capricor Therapeutics
Capricor Therapeutics Trading Down 9.8 %
The firm has a market capitalization of $591.29 million, a PE ratio of -22.11 and a beta of 4.01. The business's 50 day simple moving average is $8.45 and its two-hundred day simple moving average is $6.36.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.03). The firm had revenue of $3.97 million during the quarter, compared to the consensus estimate of $4.51 million. Capricor Therapeutics had a negative net margin of 102.93% and a negative return on equity of 220.27%. As a group, equities research analysts anticipate that Capricor Therapeutics Inc will post -1.13 earnings per share for the current year.
Insider Transactions at Capricor Therapeutics
In other Capricor Therapeutics news, major shareholder Shinyaku Co Ltd Nippon bought 2,798,507 shares of the business's stock in a transaction that occurred on Friday, September 20th. The stock was bought at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now owns 7,090,351 shares of the company's stock, valued at $38,004,281.36. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 12.00% of the company's stock.
Hedge Funds Weigh In On Capricor Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of CAPR. BNP Paribas Financial Markets purchased a new stake in Capricor Therapeutics in the first quarter worth about $40,000. Main Street Financial Solutions LLC raised its stake in Capricor Therapeutics by 37.5% during the 2nd quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company's stock worth $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC bought a new stake in Capricor Therapeutics during the 3rd quarter worth approximately $133,000. Rhumbline Advisers purchased a new position in Capricor Therapeutics during the second quarter valued at approximately $147,000. Finally, Bank of New York Mellon Corp boosted its position in shares of Capricor Therapeutics by 12.8% in the second quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company's stock worth $381,000 after purchasing an additional 9,040 shares during the period. 21.68% of the stock is currently owned by hedge funds and other institutional investors.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Further Reading
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
